BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8991117)

  • 1. Minimal residual disease in non-Hodgkin's lymphoma.
    Schultze JL; Gribben JG
    Biomed Pharmacother; 1996; 50(9):451-8. PubMed ID: 8991117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.
    Corradini P; Astolfi M; Cherasco C; Ladetto M; Voena C; Caracciolo D; Pileri A; Tarella C
    Blood; 1997 Jan; 89(2):724-31. PubMed ID: 9002976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular remission and non-Hodgkin's lymphoma.
    Darby AJ; Johnson PW
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
    Vose JM; Zhang MJ; Rowlings PA; Lazarus HM; Bolwell BJ; Freytes CO; Pavlovsky S; Keating A; Yanes B; van Besien K; Armitage JO; Horowitz MM;
    J Clin Oncol; 2001 Jan; 19(2):406-13. PubMed ID: 11208832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
    J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
    N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.
    Sweetenham JW; Proctor SJ; Blaise D; De Laurenzi A; Pearce R; Taghipour G; Goldstone AH; Laurenzi A [corrected to De Laurenzi A]
    Ann Oncol; 1994; 5 Suppl 2():155-9. PubMed ID: 7515646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.
    Ladetto M; Zallio F; Vallet S; Ricca I; Cuttica A; Caracciolo D; Corradini P; Astolfi M; Sametti S; Volpato F; Bondesan P; Vitolo U; Boccadoro M; Pileri A; Gianni AM; Tarella C
    Leukemia; 2001 Dec; 15(12):1941-9. PubMed ID: 11753616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry.
    Williams CD; Pearce R; Taghipour G; Green ES; Philip T; Goldstone AH
    J Clin Oncol; 1994 Nov; 12(11):2415-22. PubMed ID: 7964958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma.
    Lenain C; Dumontet C; Gargi T; Chassagne C; Berger F; Perol D; Garnier M; Coiffier B; Blay JY
    Hematol J; 2004; 5(5):403-9. PubMed ID: 15448666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining.
    Fisher RI
    J Natl Cancer Inst; 2001 Jan; 93(1):4-5. PubMed ID: 11136829
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A; Shi Y; Feng F; Lu S; He X; Han X
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autologous bone marrow transplantation for the treatment of malignant lymphoma in adults].
    Da WM; Zhong JT; Huang YS
    Zhonghua Nei Ke Za Zhi; 1992 Oct; 30(10):640-2, 660. PubMed ID: 1582346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
    Moos M; Schulz R; Martin S; Benner A; Haas R
    Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
    Corradini P; Ladetto M; Pileri A; Tarella C
    Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL
    N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma].
    Gisselbrecht C; Lepage E; Brice P; Trédaniel J; Gerota I
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):131-4. PubMed ID: 2455276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.